Telmisartan
Micardis
Angiotensin II receptor blocker; PPAR-γ activity may improve lipid profile on-cycle.
Key takeaways
- ARB approved for hypertension; longest half-life in class at ~23 hours, once-daily coverage.
- Partial PPAR-gamma activity may modestly improve insulin sensitivity and lipid markers.
- ONTARGET trial (25,000+ patients) showed cardiovascular protection equivalent to ramipril.
- Prophylactic use without hypertension is unproven; orthostatic hypotension is the real risk.
Overview
What it is
Telmisartan (Micardis) is an angiotensin II receptor blocker approved for hypertension. Among ARBs it's unusual for partial PPAR-gamma activity, which may modestly improve insulin sensitivity and lipid markers — one reason it's discussed in anabolic contexts where blood pressure and lipids both drift.
Pharmacokinetics
Oral bioavailability runs about 43% and drops at higher doses, plasma peaks in roughly 2 hours, and the ~23-hour half-life is the longest in the ARB class, giving true 24-hour coverage on once-daily dosing. Steady state arrives within about a week.
What the evidence says
Telmisartan is one of the most-studied antihypertensives: ONTARGET, a randomized trial of over 25,000 patients, found it equivalent to ramipril for cardiovascular protection. The PPAR-gamma metabolic benefits are real but modest, and taking it prophylactically without actual hypertension trades an unproven benefit for a real hypotension risk.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Hypertension (label) | 40 mg start; 20–80 mg | Oral | Once daily | Chronic |
Pharmacokinetic summary
- Model tier
- Advanced (t½ + Cmax + Tmax + F)
- Half-life
- 23.3 hours
- Cmax
- 770.0625 ng/mL
- Tmax
- 0.1 days
- Bioavailability
- 43%
- Typical dose
- 20–80 mg
Frequently asked questions
Why telmisartan over other blood-pressure drugs in this context?
Two reasons get cited: once-daily 24-hour coverage from the longest ARB half-life, and partial PPAR-gamma activity that may blunt some lipid and insulin-sensitivity damage from anabolic use. The metabolic effect is modest; it doesn't rescue a bad lipid panel.
Can telmisartan replace cholesterol medication?
No. Its lipid effects are small and inconsistent across trials. Genuinely abnormal lipids need their own workup and treatment; telmisartan's PPAR-gamma activity is a mild secondary property, not a therapy.
Is telmisartan safe to take without high blood pressure?
It lowers pressure regardless of starting point, so normotensive users risk dizziness and orthostatic hypotension, especially combined with other antihypertensives. The evidence base sits in hypertensive and high-cardiovascular-risk patients, not prophylactic use.
References
- PubMed telmisartan PK
- Telmisartan PK in healthy subjects (Arzneimittel-Forschung 2006) — Human PK data: half-life, Tmax, dose-dependent bioavailability.
Related compounds
Comments
Loading comments…